Ruxolitinib, a JAK1/2 inhibitor that decreased Th17 cells and increased Tregs, has been tested in a completed phase II clinical trial (NCT02876302) in inflammatory BC with paclitaxel, doxorubicin, and cyclophosphamide.239. The gene discussed is JAK1; the disease is breast cancer.